Evidence map›Paper›PMID 29609559›Full record

SynthesisBMC gastroenterology2018

Irinotecan-containing doublet treatment versus irinotecan monotherapy as second-line choice for advanced gastric cancer.

Liuting Yang, Xiaoyue Jiang, Han Yan, Yingying Li, Hongchao Zhen, Bingmei Chang, Seyed Kariminia, Qin Li

Open access · goldAbstract readMeta-AnalysisReview
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in BMC gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Liuting YangDepartment of Biochemistry and Molecular Biology, Basic Medical College, Shanxi Medical University, Taiyuan, 030001, China.
Xiaoyue JiangDepartment of Oncology, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, China.
Han YanDepartment of Oncology, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, China.
Yingying LiDepartment of Microbiology, Peking University Health Science Center, Beijing, 100190, China.
Hongchao ZhenDepartment of Oncology, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, China.
Bingmei ChangDepartment of Biochemistry and Molecular Biology, Basic Medical College, Shanxi Medical University, Taiyuan, 030001, China.
Seyed KariminiaDepartment of Molecular and Cellular Oncology, MD Anderson Cancer Center, Houston, TX, 77030, USA.
Qin LiDepartment of Oncology, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, China. oncologistinbj@163.com.ORCID http://orcid.org/0000-0002-2470-6089
Capital Medical University · CNShanxi Medical University · CNPeking University · CNThe University of Texas MD Anderson Cancer Center · US

Funding

Beijing Municipal Health System High-level Health Person Foundation Project 2014-3-005the Beijing Municipal Science and Technology Commission Foundation Z161100000516083the National Natural Science Foundation of China 81301912
6 · The paper itself

Abstract

backgroundFor patients with advanced gastric cancer (AGC), second-line chemotherapy regimen remains controversial. The efficacy and safety of irinotecan-containing doublet treatment and irinotecan monotherapy were compared in this systematic analysis.

methodsA search was conducted on EMBASE and Medline databases. All articles compared irinotecan-containing doublet to irinotecan as second-line chemotherapy for AGC. STATA statistical software (Version 12.0) was used to analyze the data.

resultsSeven studies, including 905 cases, were included in the analysis. Irinotecan-containing doublet treatment significantly prolonged progression-free survival compared to irinotecan monotherapy (HR = 0.82, 95% CI: 0.70-0.95). However, doublet treatment neither significantly prolong overall survival compared to monotherapy (HR = 0.94, 95% CI: 0.81-1.10), nor did it significantly increase the overall response rates and disease control rates, when compared to monotherapy. In addition, the irinotecan-containing doublet group had an increase in incidences of ≥ Grade 3 neutropenia (RR = 1.23, 95% CI: 1.01-1.51) and anemia (RR = 2.00, 95% CI: 1.37-2.92).

conclusionsWhen compared to irinotecan monotherapy, irinotecan-containing doublet treatment increased progression free survival and was tolerable as a second- line chemotherapy for AGC.

Indexed as

Antineoplastic Agents, PhytogenicAntineoplastic Combined Chemotherapy ProtocolsCamptothecinDisease-Free SurvivalHumansIrinotecanStomach NeoplasmsTreatment OutcomeAntineoplastic Agents, PhytogenicCamptothecinIrinotecanAdvanced gastric cancerEfficacyIrinotecanSafetySecond-line chemotherapy

Identifiers

PMID29609559
PMCPMC5879920
OpenAlexW2796096298

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.